EBR Systems (ASX:EBR) received priority review determination from the Therapeutic Goods Administration for the WiSE System, according to a Friday filing with the Australian bourse.
The WiSE System is a cardiac device capable of pacing the heart without a lead.
The determination provides an accelerated pathway for the device to be included on the Australian Register of Therapeutic Goods, the filing said.
Shares rose 7% in morning trade on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.